热门:乐视网吧 中弘股份吧 中兴通讯吧
万基遗传吧
发表于 2018-07-12 12:53:32 股吧网页版
Scale Brings Opportunity, Upgrade to Overweight 查看PDF原文

研报日期:2018-07-12

  万基遗传(MYGN)

  Stabilizing core high return capital deployment = accelerating earnings profile.

  We are upgrading MYGN to Overweight from Equal-weight as we believeMYGN's earnings profile is dramatically changing. We observe: 1) the core HCTbusiness showing durability above what bears give credit, with volumes returningto growth and price declines slowing as we outlined in our March upgrade toEqual-weight: Balanced Risk/Reward and HCT Share Improving; Upgrading toEW (21 Mar 2018); 2) Key acquisitions expanding the company's TAM intopsychiatry (Assurex) and a natural leverage point for the core OBGYN business inpre-natal (Counsyl), also diversifying into higher growth and improving ASPtesting markets; 3) Conservative estimates make MYGN appear inexpensive withthe highest FCF yield in our space at 7% on '19, despite growing FCF 30% through'21, 1000bps ahead of peers. Our EBIT estimate moves 30% higher in FY20 andabove consensus by a similar degree for the improving stabilization we see incore HCT and the inclusion of Counsyl. We believe the buyside has also not yetincorporated above dynamics into their views of the stock. Key catalysts will beFY19 annual guidance, including Counsyl expected during earnings in August thatwe expect can drive consensus '19 estimates 10% higher. We raise our PT from$35 to $55 based on our DCF, implying a 5% FCF yield and 25x FY20e EPS, belowpeers on FCF trading at 4% despite growing FCF 1000bps faster over the next 3years.

  Risks are noteworthy, but our model leaves margin for error. While we note thatthe bears on MYGN are correct that there is limited visibility on the pace ofGenesight reimbursement, Counsyl share trends, or hereditary cancer/HCTpricing trends, we took a conservative view on each of these points in buildingour updated forecasts. 1) Genesight: our ASP trend assumes less than half ofpayors reimburse at target levels as far out as 2022, in spite of supportive clinicaland cost-benefit data; 2) Counsyl: we assume shar……[摩根士丹利]
[点击查看PDF原文] 今日最新研究报告

提示:本文属于研究报告栏目,仅为机构或分析人士对一只股票的个人观点和看法,并非正式的新闻报道,本网不保证其真实性和客观性,一切有关该股的有效信息,以沪深交易所的公告为准,敬请投资者注意风险。
作者:您目前是匿名发表   登录 | 5秒注册 作者:,欢迎留言 退出 | 发表新主题
提示:用户在社区发表的所有资料、言论等仅代表个人观点,与本网站立场无关,不对您构成任何投资建议。用户应基于自己的独立判断,自行决定证券投资并承担相应风险。《跟帖评论自律管理承诺书》

研报日期:2018-07-12

  万基遗传(MYGN)

  Stabilizing core high return capital deployment = accelerating earnings profile.

  We are upgrading MYGN to Overweight from Equal-weight as we believeMYGN's earnings profile is dramatically changing. We observe: 1) the core HCTbusiness showing durability above what bears give credit, with volumes returningto growth and price declines slowing as we outlined in our March upgrade toEqual-weight: Balanced Risk/Reward and HCT Share Improving; Upgrading toEW (21 Mar 2018); 2) Key acquisitions expanding the company's TAM intopsychiatry (Assurex) and a natural leverage point for the core OBGYN business inpre-natal (Counsyl), also diversifying into higher growth and improving ASPtesting markets; 3) Conservative estimates make MYGN appear inexpensive withthe highest FCF yield in our space at 7% on '19, despite growing FCF 30% through'21, 1000bps ahead of peers. Our EBIT estimate moves 30% higher in FY20 andabove consensus by a similar degree for the improving stabilization we see incore HCT and the inclusion of Counsyl. We believe the buyside has also not yetincorporated above dynamics into their views of the stock. Key catalysts will beFY19 annual guidance, including Counsyl expected during earnings in August thatwe expect can drive consensus '19 estimates 10% higher. We raise our PT from$35 to $55 based on our DCF, implying a 5% FCF yield and 25x FY20e EPS, belowpeers on FCF trading at 4% despite growing FCF 1000bps faster over the next 3years.

  Risks are noteworthy, but our model leaves margin for error. While we note thatthe bears on MYGN are correct that there is limited visibility on the pace ofGenesight reimbursement, Counsyl share trends, or hereditary cancer/HCTpricing trends, we took a conservative view on each of these points in buildingour updated forecasts. 1) Genesight: our ASP trend assumes less than half ofpayors reimburse at target levels as far out as 2022, in spite of supportive clinicaland cost-benefit data; 2) Counsyl: we assume shar……[摩根士丹利]
[点击查看PDF原文] 今日最新研究报告

提示:本文属于研究报告栏目,仅为机构或分析人士对一只股票的个人观点和看法,并非正式的新闻报道,本网不保证其真实性和客观性,一切有关该股的有效信息,以沪深交易所的公告为准,敬请投资者注意风险。
东方财富

扫一扫下载APP
天天基金

扫一扫下载APP
信息网络传播视听节目许可证:0908328号 经营证券期货业务许可证编号:913101046312860336 违法和不良信息举报:021-34289898 举报邮箱:jubao@eastmoney.com
沪ICP证:沪B2-20070217 网站备案号:沪ICP备05006054号-11 沪公网安备 31010402000120号 版权所有:东方财富网 意见与建议:021-54509966/021-24099099